#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    MELAS syndrome B-cell small lymphocytic lymphoma refractory Glomerulonephritis membranous Metachromatic leukodystrophy Von Hippel-Lindau disease Small cell lung cancer recurrent Pemphigus Immunoglobulin G4 related disease Anti-myelin-associated glycoprotein associated polyneuropathy Pseudomyxoma peritonei Renal cell carcinoma Hyperinsulinaemic hypoglycaemia IgA nephropathy Amyotrophic lateral sclerosis gene carrier Leiomyosarcoma metastatic More trials…

    Learn about Rare Diseases

    Epidermolysis bullosa – Life with Disease Epidermolysis bullosa – Basic Information Encephalitis autoimmune – Life with Disease Bronchopulmonary dysplasia – Diagnostics Behcet’s syndrome – Basic Information Inclusion body myositis Glomerulonephritis membranous – Diagnostics Alexander disease Haemolytic uraemic syndrome – Trials in Disease Toxic epidermal necrolysis – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dordaviprone GS-248 Teplizumab Olive Oil, Refined Hydralazine Hydrochloride Bi 3720931 TRIGLYCERIDES MEDIUM CHAIN Afm24 Allo-501A Mycophenolate Sodium Benzocaine Ceftazidime Pentahydrate Vortioxetine Hydrobromide Trifluridine Dexketoprofen Finerenone Darovasertib Rifamycin Sodium Deucrictibant Ammonium Chloride Bp More therapies…

    Learn about Your Condition

    Hyperglycaemia Follicular lymphoma stage III Gout B-cell lymphoma recurrent Contusion Migraine with aura Diabetic gastroparesis Glomerulonephritis membranous Dermatitis Uveal melanoma Lipid metabolism disorder Normal pressure hydrocephalus Kaposi's sarcoma Microscopic polyangiitis Inner ear disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Virus Diseases

  • Study on the Safety and Immune Response of BIMERVAX as a COVID-19 Booster in Adolescents Aged 12 to 17 Years

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • COVID-19
    Investigated Drugs:
    • SARS-COV-2 VIRUS, VARIANTS B.1.351-B.1.1.7, SPIKE PROTEIN, RECEPTOR BINDING DOMAIN FUSION HETERODIMER
    Spain

  • Study on the Immune Response and Safety of RSVPreF3 Vaccine in Adults 18-49 at Risk for Respiratory Syncytial Virus Compared to Adults 60 and Older

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Respiratory syncytial virus bronchiolitis
    • Respiratory syncytial virus infection
    Investigated Drugs:
    • Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
    Germany

  • Study on Intradermal COVID-19 mRNA Vaccine (Tozinameran, Famtozinameran) for Elderly Patients Aged 75 and Older

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Tozinameran
    The Netherlands

  • Study on the Immune Response and Safety of RSVPreF3 OA Vaccine Alone and with COVID-19 mRNA Vaccine in Adults Aged 50 and Above

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Raxtozinameran
    • Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
    Belgium The Netherlands Spain

  • Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
    Belgium Estonia Finland Germany Italy Poland +1

  • Study on the 9vHPV Vaccine for Preventing Oral HPV Infections in Men Aged 20-45

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Papilloma viral infection
    Investigated Drugs:
    • Human Papillomavirus Type 11 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
    • Human Papillomavirus Type 16 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
    • Human Papillomavirus Type 18 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
    Belgium Czechia France Germany Italy Spain
Previous Page
1 … 29 30 31 32 33 … 51
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!